SR

Shravani Ramling Gat

Active Director Designated Partner DIN 11594505
DIN 11594505 First appointment Mar 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Shravani Ramling Gat

Data last updated:

Shravani Ramling Gat is a Designated Partner at Oncocare Pharma Distributor Limited Liability Partnership (since 2026).

DIN 11594505
Primary Designation Designated Partner
First Appointment 10 Mar 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner10 Mar 20262026Active

Directorship timeline

Open interactive timeline →
Oncocare Pharma Distributor Limited Liability Partnership
Premium access

Shareholding and investment profile for Shravani Ramling Gat

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shravani Ramling Gat

Shravani Ramling Gat currently holds 1 directorship: Oncocare Pharma Distributor Limited Liability Partnership (Designated Partner, since 10 Mar 2026).

Shravani Ramling Gat was first appointed on 10 Mar 2026 as Designated Partner at Oncocare Pharma Distributor Limited Liability Partnership.

The current boards of Shravani Ramling Gat's companies include Abhijeet Ashok Kokate (Oncocare Pharma Distributor Limited Liability Partnership), Shivaji Subhash Salunke (Oncocare Pharma Distributor Limited Liability Partnership), Supriya Bhausaheb Pawale (Oncocare Pharma Distributor Limited Liability Partnership).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available